BSE filing, NSE: TRIMURTHI. Summary written from the filing by ALFA Finder's alert engine.
Novelix Pharmaceuticals Ltd: key numbers
- Share price
- ₹64.66
- Market cap
- ₹113.9 Cr
- Revenue (annual)
- ₹132.3 Cr
- Net profit (annual)
- ₹2.56 Cr
- P/E (TTM)
- 31.4×Sector 64.4×
- Promoter holding
- 54.29%+3.72% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novelix Pharmaceuticals Ltd
All →Novelix Pharmaceuticals Board Meeting Date
Novelix Pharmaceuticals has given prior intimation of a board meeting on 11 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The trading window stays closed until forty-eight hours after the meeting.
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals Ltd has filed its quarterly shareholding pattern as per SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Novelix Pharmaceuticals Management Change
Novelix Pharmaceuticals announced the appointment of Mr. Gnana Prakash Gattu as Whole Time Director, approved by shareholders at the company's 32nd Annual General Meeting.
Novelix Pharmaceuticals Annual General Meeting
Novelix Pharmaceuticals held its 32nd Annual General Meeting on 30th September, 2026, transacting ordinary and special business items via e-voting and video conferencing.
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.
Novelix Pharmaceuticals Annual Report
Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.
Other board meeting outcome announcements
All →Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.
BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.
Voltas Board Meeting Outcome
Voltas Limited's board approved Deloitte Haskins & Sells as statutory auditors for five years from the 73rd AGM, replacing SRBC & Co. LLP, whose second and final term ends at that AGM. Subject to shareholder approval.
- Execution
- Five years: financial years 2027-28 to 2031-32 (from the 73rd AGM in 2027 to the 78th AGM in 2032)
CMX Holdings Board Meeting Outcome
Riwind Green Energy (formerly CMX Holdings) board approved altering its MOA main objects into six consolidated objects and a postal ballot notice. The change refocuses the company on solar, EPC, battery storage and renewable data-centre businesses.